Tvardi Therapeutics Reports Q3 2026 Results; Net Loss Widens to $6.1M on Higher R&D Spend
Tvardi Therapeutics reported a Q3 2026 net loss of $6.1 million compared to a net loss of $5.5 million in Q3 2025, as R&D expenses increased to $4.5 million from $3.6 million driven by higher clinical costs for TTI-101. Basic and diluted net loss per share improved to $(0.48) from $(0.59) year-over-year. The company ended Q3 2026 with $22.3 million in cash and cash equivalents, down from $30.8 million at year-end 2025, and expects this to fund operations into Q3 2027.
Key takeaways
Net loss widened to $6.1 million in Q3 2026 versus $5.5 million in Q3 2025, driven by increased R&D spending on TTI-101 clinical trials.
Basic and diluted EPS improved to $(0.48) from $(0.59) year-over-year due to higher share count from equity financings.
Cash position declined to $22.3 million as of September 30, 2026, from $30.8 million at December 31, 2025, with runway expected into Q3 2027.
TTI-109 ulcerative colitis program advancing toward IND filing and Phase 1 trial initiation in 2027, subject to regulatory clearance and additional funding.
TTI-101 hepatocellular carcinoma Phase 1b/2 REVERT LIVER CANCER study on track for topline data in early Q1 2027.
Nine-month net loss widened to $19.4 million from $10.9 million in the prior-year period, partly due to $7.2 million other income recorded in Q1 2025.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow TVRD in real time
Get material earnings, filing, IR, and earnings-call alerts by email.